SELLAS Life Sciences Group, Inc. (SLS)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, SELLAS Life Sciences Group, Inc. reported net income of -$9.6M and total assets of $145.4M. Every figure below is taken directly from SELLAS Life Sciences Group, Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2019–FY2023 · as reported
- FY2019 revenue
- $0
- FY2023 revenue
- $0
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | — | -$26.9M |
| FY2024 | — | -$30.9M |
| FY2023 | $0 | -$37.3M |
| FY2022 | $1.0M | -$41.3M |
| FY2021 | $7.6M | -$20.7M |
| FY2020 | $1.9M | -$16.8M |
| FY2019 | $0 | -$19.3M |
| FY2018 | — | -$27.7M |
| FY2017 | — | -$23.8M |
| FY2016 | — | -$17.7M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Aug 11, 2026 | on EDGAR ↗ |
| 10-Q | Aug 11, 2026 | on EDGAR ↗ |
| 8-K | Jul 27, 2026 | on EDGAR ↗ |
| 8-K | Jun 25, 2026 | on EDGAR ↗ |
| 8-K | Jun 18, 2026 | on EDGAR ↗ |
| 8-K | Jun 2, 2026 | on EDGAR ↗ |
| 10-Q | May 12, 2026 | on EDGAR ↗ |
| 8-K | May 12, 2026 | on EDGAR ↗ |
| DEF 14A | Apr 23, 2026 | on EDGAR ↗ |
| 8-K | Mar 19, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-0.05 | Earnings | source ↗ |
| EPS (basic) | $-0.05 | Earnings | source ↗ |
| Shares Outstanding | 201.9M | Entity | source ↗ |
| Cash from Operations | -$7.6M | Net | source ↗ |
| Cash from Financing | $38.8M | Net | source ↗ |
| Cash from Investing | — | — | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
Restatement history
Point-in-time27 of 352 annual fact-keys were materially restated between filings: what SELLAS Life Sciences Group, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches SLS’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/SLS
MCP tool:
get_sec_fundamentals ticker=SLS - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/SLS/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=SLS as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/SLS/history
MCP tool:
get_fundamentals_history ticker=SLS - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/SLS
MCP tool:
get_financial_health ticker=SLS
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.